Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ARMP 
Armata Pharmaceuticals Inc (ARMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.63% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 125.90M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 1.13 | 52 Weeks Range 0.90 - 3.50 | Updated Date 10/20/2025 |
52 Weeks Range 0.90 - 3.50 | Updated Date 10/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -315.54% |
Management Effectiveness
Return on Assets (TTM) -23.35% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 250812762 | Price to Sales(TTM) 18.33 |
Enterprise Value 250812762 | Price to Sales(TTM) 18.33 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 15.72 | Shares Outstanding 36229842 | Shares Floating 10874749 |
Shares Outstanding 36229842 | Shares Floating 10874749 | ||
Percent Insiders 69.48 | Percent Institutions 2.02 |
Upturn AI SWOT
Armata Pharmaceuticals Inc
Company Overview
History and Background
Armata Pharmaceuticals, Inc. (ARMP) is a biotechnology company focused on developing and commercializing pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections. Founded in 2003, initially as AmpliPhi Biosciences, the company rebranded as Armata in 2019 to reflect its focus on phage-based antimicrobials. It has gone through several phases of research, clinical trials, and strategic shifts.
Core Business Areas
- Phage Therapeutics Development: Armata's primary focus is on discovering, developing, and commercializing bacteriophage-based therapies to combat antibiotic-resistant bacterial infections. They target specific pathogens with engineered phages.
Leadership and Structure
Armata Pharmaceuticals is led by a management team with experience in biotechnology and pharmaceutical development. Its organizational structure includes research and development, clinical operations, and business development functions. Hal Barron serves as Chairman of the Board. Brian Varnum is the CEO.
Top Products and Market Share
Key Offerings
- AP-PA02: An investigational bacteriophage therapeutic targeting Pseudomonas aeruginosa. It is in clinical development. Limited market share data is available as the product is not yet commercially available. Competitors include traditional antibiotics (resistance is a problem) and other companies developing novel antimicrobials.
- AP-SA02: An investigational bacteriophage therapeutic targeting Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). It is in preclinical development. Limited market share data is available as the product is not yet commercially available. Competitors include traditional antibiotics (resistance is a problem) and other companies developing novel antimicrobials.
Market Dynamics
Industry Overview
The industry is focused on developing novel anti-infectives to combat the rise of antibiotic-resistant bacteria. This includes phage therapy, new classes of antibiotics, and other alternative approaches.
Positioning
Armata is positioned as a company specializing in phage therapy, which is an alternative to traditional antibiotics. Its competitive advantage lies in its proprietary phage development platform and its focus on specific bacterial pathogens.
Total Addressable Market (TAM)
The global anti-infectives market is estimated to be worth billions of dollars. Armata is positioned to capture a segment of this market with its phage therapy platform, particularly for resistant infections. Estimates vary widely, but the antibiotic resistance market itself can reach $40-50 billion annually.
Upturn SWOT Analysis
Strengths
- Specialized phage therapy platform
- Targeted approach to specific bacterial pathogens
- Potential to overcome antibiotic resistance
- Experienced leadership team
Weaknesses
- Limited clinical data to date
- High regulatory hurdles for phage therapy
- Reliance on external funding
- Small company size
Opportunities
- Growing market for novel anti-infectives
- Increasing prevalence of antibiotic-resistant infections
- Potential for partnerships with larger pharmaceutical companies
- Favorable regulatory pathways for phage therapy
Threats
- Competition from established pharmaceutical companies
- Failure to obtain regulatory approval
- Slow adoption of phage therapy by physicians
- Potential for phage resistance to develop
Competitors and Market Share
Key Competitors
- Bacteriophage US Stock Symbol
- Adaptive Phage Therapeutics US Stock Symbol
- Intron Biotechnology US Stock Symbol
Competitive Landscape
Armata faces competition from other companies developing novel anti-infectives, including phage therapy and traditional antibiotics. Its advantages lie in its targeted phage therapy platform, but it faces disadvantages related to its smaller size and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by advances in its phage therapy platform and clinical trial initiations.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its lead product candidates. Analyst estimates depend on these successful products and are very speculative.
Recent Initiatives: Recent initiatives include advancing its lead product candidates through clinical trials, exploring partnerships with larger pharmaceutical companies, and expanding its phage discovery platform.
Summary
Armata Pharmaceuticals is a company specializing in phage therapy for antibiotic-resistant infections, holding promise but facing challenges. Its success hinges on clinical trial outcomes and regulatory approvals. While the market offers opportunities, competition and funding constraints are crucial considerations. The company is focused on advancing its lead candidates and forging partnerships, but near-term financial performance and investor confidence remain key risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and is subject to change. Investment decisions should be made based on individual due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com | ||
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.